|
A cannabinoid drug that was first developed by a group of Dalhousie University researchers in Halifax to treat inflammation may be a new contender in the fight against COVID-19.
The drug, called PPP003, would help prevent the onset of acute respiratory distress syndrome (ARDS), which causes death in severely ill COVID-19 patients.
|